Back to search

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-AblDOI 10.1016/j.ccr.2005.03.026
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.Semantic proximity
HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistanceSemantic proximity
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.Semantic proximity
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.Semantic proximity
AMN107: tightening the grip of imatinib.Semantic proximity
The second generation of BCR-ABL tyrosine kinase inhibitors.Semantic proximity
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.Semantic proximity
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceSemantic proximity
Mechanisms of resistance to BCR-ABL and other kinase inhibitorsSemantic proximity
ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid LeukemiaSemantic proximity
Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.Semantic proximity
The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.Semantic proximity
Select a neighboring publication to make it the new centre.